Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amesite Inc. filings document an emerging growth, smaller reporting company whose common stock trades on Nasdaq under AMST. Recent Form 8-K disclosures cover material agreements, Regulation FD shareholder updates, Nasdaq continued-listing matters, changes in the company’s independent registered public accounting firm, and updates on the NurseMagic AI-native documentation and workflow platform for non-acute care.
The company’s registration and financing filings describe securities offerings, shelf registration use, common stock, pre-funded warrants, private-placement warrants, resale registration matters, and related stockholder-approval mechanics. These filings also provide formal disclosure on capital structure, governance, risk factors, and public-company reporting obligations.
Amesite Inc. director Barbie Brewer exercised restricted stock units that had vested into common shares. On March 7, 2026, she converted 41,322 restricted stock units into 41,322 shares of Amesite common stock at a stated price of $0.00 per share as part of her equity compensation.
These restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026. Following the conversion, Brewer directly holds 135,977 shares of Amesite common stock, and there are no remaining derivative positions from this RSU grant disclosed in the filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, exercised 41,322 restricted stock units into the same number of Amesite common shares on March 7, 2026. These RSUs were granted on March 7, 2025 and vested one year later. Following the transaction, the trust holds 143,699 shares of Amesite common stock indirectly. This is a compensation-related derivative exercise with no open-market buying or selling disclosed.
Amesite Inc. director J. Michael Losh reported a routine equity compensation event involving restricted stock units held through a trust. On March 7, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 exercised 41,322 restricted stock units granted on March 7, 2025, converting them into 41,322 shares of Amesite common stock at no cash exercise price. Following the conversion, the trust holds 138,200 shares of common stock indirectly on behalf of Losh. Each restricted stock unit represented a right to receive one share of Amesite common stock or its cash equivalent upon vesting.
Amesite Inc. director J. Michael Losh reported an equity compensation award made through an associated trust. On February 6, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 received 49,751 restricted stock units (RSUs) of Amesite at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The RSUs fully vest on the first anniversary of the grant date, after which the trust will be entitled to the underlying shares or cash value.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, reported an award of 49,751 restricted stock units (RSUs) of Amesite Inc. on February 6, 2026, at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock and/or the cash equivalent of one share. The RSUs fully vest on the first anniversary of the grant date, and the trust holds 49,751 derivative securities after this transaction.
Amesite Inc. director George Parmer reported an equity award in the form of derivative securities. On February 6, 2026, he received 49,751 restricted stock units (RSUs) at a price of $0 per unit. Each RSU represents a contingent right to receive one share of AMST common stock and/or the cash equivalent.
The RSUs fully vest on the first anniversary of the grant date, and Parmer now directly holds 49,751 derivative securities linked to Amesite common stock as a result of this award.
Amesite Inc. director Barbie Brewer received a grant of 49,751 restricted stock units (RSUs) on February 6, 2026. Each RSU represents a right to receive one share of Amesite common stock or its cash equivalent. The RSUs fully vest on the first anniversary of the grant date, giving Brewer potential future ownership if service-based conditions are satisfied.
Amesite Inc. reports sharply higher revenue but continues to operate at a loss and faces going concern and listing risks. Net revenue for the six months ended December 31, 2025 rose to $202,346 from $24,010 a year earlier, with the quarter at $108,050 versus $12,760.
Cost-cutting reduced the six‑month net loss to about $1.37 million from $2.03 million, as general and administrative, technology, and sales and marketing expenses all declined. Cash, cash equivalents, and restricted cash fell to $1.27 million from $2.43 million at June 30, 2025, as operations used over $1.03 million of cash.
Management states there is substantial doubt about Amesite’s ability to continue as a going concern absent additional financing, and plans may include further common stock offerings. The company also discloses a Nasdaq deficiency notice for not meeting the $2.5 million stockholders’ equity requirement, with an extension to April 27, 2026 to regain compliance.
Amesite Inc. (AMST) furnished a Regulation FD update. The company announced the release of a shareholder update video and provided two exhibits: a press release and the video transcript. The materials are furnished under Item 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings.
Exhibit 99.1 contains the press release dated October 30, 2025, and Exhibit 99.2 contains the transcript. Exhibit 104 is the cover page Inline XBRL.
Amesite Inc. reported a Nasdaq compliance deficiency. On October 28, 2025, the company received a notice that it no longer satisfies Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The notice also states the company is not meeting alternative standards, including a $35 million market value of listed securities or $500,000 in net income in the most recent fiscal year or in two of the last three years.
Amesite has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 calendar days from the notice date to evidence compliance. If the plan is not accepted or compliance is not achieved within the extension, the company can request a hearing before an independent panel.
The notice has no immediate effect on listing or trading. Amesite’s common stock will continue to trade on the Nasdaq Capital Market under the symbol AMST.